Provided by Tiger Trade Technology Pte. Ltd.

HENGRUI PHARMA

44.320
-0.680-1.51%
Volume:1.89M
Turnover:84.13M
Market Cap:294.15B
PE:32.14
High:45.500
Open:45.500
Low:44.260
Close:45.000
52wk High:94.869
52wk Low:43.020
Shares:6.64B
HK Float Shares:258.00M
Volume Ratio:1.57
T/O Rate:0.73%
Dividend:0.23
Dividend Rate:0.53%
EPS(LYR):1.379
ROE:12.46%
ROA:7.02%
PB:3.90
PE(LYR):32.14
PS:8.03

Loading ...

Hengrui Pharma Gets Nod to Trial Drug Combination for Hepatocellular Carcinoma

MT Newswires Live
·
Jul 03

Hengrui Pharma Reports Cumulative Share Buyback Totaling 13.47 Million A-Shares as of June 30

Stock News
·
Jul 02

Hengrui Pharma Gains Regulatory Nod for Clinical Trials of Three Drug Candidates

Stock News
·
Jul 02

HENGRUI PHARMA Keeps H-Share Capital Steady, Ups A-Share Treasury Stock via RMB 66.1 Million Buy-back in June

Bulletin Express
·
Jul 02

Hengrui Pharma Shares Surge Over 6% on New Drug Indication Approval and International Expansion Success

Stock News
·
Jul 02

Movement Alert|Hengrui Pharma Rises 3.72% in Regular Trading, Pharmaceutical Sector Rally and Multiple Drug Approvals Drive Gains

Market Focus
·
Jul 02

AH Share Premium and Deviation Rankings as of July 1st Close

Stock News
·
Jul 01

AH Share Premium and Deviation Rankings as of June 30th Close

Stock News
·
Jun 30

AH Share Premium and Deviation Data for June 29th

Stock News
·
Jun 29

Movement Alert|Hengrui Pharma Rises 3.02% in Regular Trading, Pharma Sector Rallies as Multiple Regulatory Milestones Boost Sentiment

Market Focus
·
Jun 29

AH Share Premium and Deviation Rankings for June 26

Stock News
·
Jun 26

Hengrui Pharma Gets Nod to Trial HRS-4508 Tablets As Advanced Tumor Treatment; Shares Down 4%

MT Newswires Live
·
Jun 26

Hengrui Pharmaceuticals Unit Wins China Approval to Expand Indication of Cancer Drug

MT Newswires Live
·
Jun 26

Movement Alert|Hengrui Pharmaceuticals Falls 3.53% in Regular Trading, Trading at 54.15 HKD

Market Focus
·
Jun 26

Hengrui Pharmaceuticals Unit Wins China Marketing Approval for Dry Eye Drug

MT Newswires Live
·
Jun 26

Hengrui Pharma Secures NMPA Approval for Adebrelimab as China’s First Domestic Peri-operative PD-L1 Therapy for Resectable NSCLC

Bulletin Express
·
Jun 25

Hengrui Pharma secures NMPA green light for China’s first 0.1% water-free cyclosporine eye-drop

Bulletin Express
·
Jun 25

Hengrui Pharma's Adebrelimab Injection Gains Approval for Additional NSCLC Perioperative Indication

Stock News
·
Jun 25

Jiangsu Hengrui Pharmaceuticals - Subsidiary Received Notification from Nmpa Approving New Indication for Adebrelimab Injection

THOMSON REUTERS
·
Jun 25

AH Share Premium and Deviation Rankings as of June 24th Close

Stock News
·
Jun 24